The list shows the financial contributions granted in 2012.
Aargau Cancer League
Kuehni Claudia E. | CHF 60,000.–
Bereich Internationale Gesundheit und Umwelt und Schweizer Kinderkrebsregister (SKKR), Institut für Sozial- und Präventivmedizin, Universität Bern, Bern
The educational situation in childhood cancer survivors in Switzerland
Basel Cancer League
Bentires-Alj Mohamed | CHF 50,000.–
Friedrich Miescher Institut für biomedizinische Forschung (FMI), Basel
Inhibition of the calcium-activated chloride channel TMEM16A / ANO1 reduces breast cancer growth Bubendorf Lukas | CHF 15,000.–
Institut für Pathologie, Universitätsspital Basel, Basel
Diagnostic significance of ERG expression in biopsies of early detected prostate cancer Chiquet-Ehrismann Ruth | CHF 50,000.–
Friedrich Miescher Institut für biomedizinische Forschung (FMI), Basel
SAP-dependent MKL1 signalling in tumour progression Hemmings Brian A. | CHF 50,000.–
Friedrich Miescher Institut für biomedizinische Forschung (FMI), Basel
DNA damage-mediated HSET-dependence in cancer cells and its potential for cancer therapy Iezzi Giandomenica | CHF 12,500.–
Departement Biomedizin, Universitätsspital Basel, Basel
Phenotypic and functional characterization of tumour-infiltrating and peripheral blood monocyte subsets from patients with colorectal cancer
Kind André B. | CHF 20,000.–
Frauenklinik, Universitätsspital Basel, Basel
Human papillomavirus types in cervical cancer in Malawi – do we have the right vaccine to start immunization? Mindt Thomas L. | CHF 12,500.–
Klinik für Radiologie und Nuklearmedizin, Universitätsspital Basel, Basel
Novel antagonistic radiopeptide mimetics for the diagnosis and therapy of cancer Rentsch Cyrill A. | CHF 15,000.–
Urologische Klinik, Universitätsspital Basel, Basel
New markers for treatment response to radiotherapy in prostate cancer Sommer Gregor | CHF 5000.–
Klinik für Radiologie und Nuklearmedizin, Universitätsspital Basel, Basel
Assessment of treatment response in patients with metastatic neuroendocrine carcinoma under metabolic radionuclide therapy with 90Y-DOTATOC using diffusion- and perfusion-weighted magnetic resonance imaging Tzankov Alexandar | CHF 50,000.–
Institut für Pathologie, Universitätsspital Basel, Basel
Bern Cancer League
Gautschi Oliver | CHF 59,000.–
Medizinische Onkologie, Luzerner Kantonsspital, Luzern
SAKK 19 /09: bevacizumab, pemetrexed and cisplatin, or erlotinib and bevacizumab for advanced non-squamous NSCLC stratified by EGFR mutation status. A multicentre phase II trial including biopsy at progression (BIO-PRO trial)
Karamitopoulou-Diamantis Eva | CHF 70,000.–
Institut für Pathologie, Universität Bern, Bern
Role of microRNAs and PTEN /PI3K /AKT pathway in pancreatic cancer progression from localized to metastatic disease: relationship to tumour budding, prognosis and response to adjuvant therapy
Novak Urban | CHF 75,000.–
Universitätsklinik für Medizinische Onkologie, Inselspital, Universitätsspital Bern, Bern
Whole-exome sequencing of aggressive mediastinal lymphomas in two female siblings Pabst Thomas | CHF 50,000.–
Universitätsklinik für Medizinische Onkologie, Inselspital, Universitätsspital Bern, Bern
Randomized evaluation of vinorelbine versus gemcitabine for mobilization of peripheral stem cells in myeloma patients undergoing autologous stem cell transplantation
Reyes Mauricio | CHF 30,000.–
Institut für Chirurgische Technologien und Biomechanik (ISTB), Universität Bern, Bern
40
Saurer Leslie | CHF 45,000.–
Institut für Pathologie, Universität Bern, Bern
Significance of triggering receptor expressed on myeloid cells-1 (TREM-1) in experimental colorectal cancer (CRC) development and its role as prognostic marker in human CRC
Schardt Julian | CHF 30,000.–
Institut für Medizinische Onkologie, Inselspital, Universitätsspital Bern, Bern
Investigating the combined cytotoxic effect of the Cox-2 inhibitor celecoxib and the proteasome inhibitor bortezomib in leukaemic cells
Schmitt Kurrer Anja Maria | CHF 76,000.–
Institut für Pathologie, Universität Bern, Bern
The role of angiogenesis and hypoxia signalling in the response prediction to targeted therapy of pancreatic neuroendocrine tumours pNET
von Gunten Stephan | CHF 55,000.–
Institut für Pharmakologie, Universität Bern, Bern
Siglec-7 and Siglec-9 receptors on NK cells: expression and function in cancer
Central Switzerland Cancer League
Diebold Joachim | CHF 50,000.–
Zentralschweizer Krebsregister, Luzerner Kantonsspital, Luzern
Do the new possibilities for targeted therapy lead to an improvement in survival rates of advanced lung cancer patients in central Switzerland?
Heinimann Karl | CHF 60,000.–
Forschungsgruppe Humangenetik, Universität Basel, Basel
Comprehensive genetic analysis of Lynch syndrome colorectal cancers by exome-wide sequencing
Eastern Switzerland Cancer League
Böhm Steffen | CHF 20,000.–
Centre for Cancer & Inflammation, Queen Mary University, London, United Kingdom
Interleukin-6 in high-grade serous ovarian cancer Ludewig Burkhard | CHF 100,000.–
Institut für Immunbiologie, Kantonsspital St. Gallen, St. Gallen
Systems biology approach to molecularly characterize the lung cancer microenvironment
Geneva Cancer League
Ansari Marc | CHF 80,000.–
Département de pédiatrie, Hôpitaux universitaires de Genève (HUG), Genève
Pharmacogenomics of childhood cancer Clement-Schatlo Virginie | CHF 200,000.–
Service de neurochirurgie, Département des neurosciences cliniques, Hôpitaux universitaires de Genève (HUG), Genève
The biology of cancer-initiating cells Cohen Marie | CHF 109,168.–
Département de gynécologie et d’obstétrique, Hôpitaux universitaires de Genève (HUG), Genève
Novel therapeutic approaches against ovarian cancer recurrence Dietrich Pierre-Yves | CHF 135,000.–
Service d’oncologie, Département de médecine interne, Hôpitaux universitaires de Genève (HUG), Genève
41 Irminger Irmgard | CHF 50,000.–
Département de gynécologie et d’obstétrique, Hôpitaux universitaires de Genève (HUG), Genève
Regulation of the oncogenic isoforms of the tumour suppressor BARD1 in cancer by microRNAs and non-coding RNAs
Kruithof Egbert | CHF 50,000.–
Faculté de médecine, Hôpitaux universitaires de Genève (HUG), Genève
Epigenetic regulation of tissue factor and plasminogen activator in acute promyelocytic leukaemia cells Mandriota Stefano | CHF 25,000.–
Département de pédiatrie, Division d’onco-hématologie, Hôpitaux universitaires de Genève (HUG), Genève
Assessment of the carcinogenicity of aluminium chloride in human mammary gland epithelial cells Mandriota Stefano | CHF 100,230.–
Département de pédiatrie, Division d’onco-hématologie, Hôpitaux universitaires de Genève (HUG), Genève
The ATM /p53 signalling pathway in the regulation of cellular senescence Reith Walter | CHF 111,159.–
Département de pathologie et d’immunologie, Faculté de médecine, Université de Genève, Genève
Identifying the cellular functions and regulatory networks that underlie the link between microRNA-155 and cancer
Thore Stéphane | CHF 90,000.–
Département de biologie moléculaire, Faculté des sciences, Université de Genève, Genève
Steroid receptor RNA activator: a new target for modulating the hormonal response in cancer cells Tille Jean-Christophe | CHF 70,000.–
Département de pathologie clinique, Faculté de médecine, Université de Genève, Genève
Role of heparan sulfate in endometrioid carcinoma: tissue remodelling, angiogenesis and lymphangiogenesis Zaïdi Habib | CHF 111,337.–
Département de radiologie, Faculté de médecine, Université de Genève, Genève
Multitracer molecular imaging of tumour metabolism, cell proliferation and hypoxia: a pathway to personalized targeted therapy
Grisons Cancer League
von Moos Roger | CHF 5,000.–
Medizinische Onkologie und Hämatologie, Kantonsspital Graubünden, Chur
Patient management study: telephone follow-up regarding new symptoms during treatment with oral fluoropyrimidine
Neuchâtel Cancer League
Registre neuchâtelois des tumeurs | CHF 144,037.–
Registre neuchâtelois des tumeurs, Neuchâtel
Contribution to the cancer registry
Thurgau Cancer League
Kodex-Stiftung | CHF 3,000.–
Kodex-Stiftung für Suchtmittel-Prävention, Frauenfeld
Contribution to the Kodex programme Krebsregister Thurgau | CHF 30,000.–
Thurgauische Stiftung für Wissenschaft und Forschung, Frauenfeld
42
Ticino Cancer League (Fondazione ticinese per la ricerca sul cancro)
Bertoni Francesco | CHF 80,000.–
Laboratorio di oncologia sperimentale, Istituto oncologico della Svizzera italiana (IOSI), Bellinzona
The methylome of splenic marginal zone lymphoma: an integration of epigenetic, genetic and clinical data Frattini Milo | CHF 50,000.–
Istituto cantonale di patologia, Locarno
Investigation of the role of NEU3 in colorectal carcinogenesis and in the prediction of efficacy of EGFR targeted therapies
Grassi Fabio | CHF 40,000.–
Istituto di ricerca in biomedicina (IRB), Bellinzona
Purinergic signalling in the pathophysiology of central nervous system infiltration in T-cell leukaemia Thelen Markus | CHF 40,000.–
Istituto di ricerca in biomedicina (IRB), Bellinzona
Detailed study of the interactions and subcellular distribution of the tumourigenic chemokine receptor CXCR7/RDC1 in lymphocytes
Zurich Cancer League
Bernasconi Michele | CHF 66,300.–
Experimentelle Infektiologie und Krebsforschung, Kinderspital Zürich, Universitäts-Kinderkliniken, Zürich
Role of proprotein convertases in paediatric sarcomas: useful theragnostic targets? Bornhauser Beat | CHF 61,300.–
Forschungsgruppe Leukämie /Onkologie, Kinderspital Zürich, Universitäts-Kinderkliniken, Zürich
Large scale drug response profiling to identify new targets in refractory leukaemia Cancer Network Zurich | CHF 10,000.–
Universität Zürich, Zürich
Contribution to the 2012 symposium Dedes Konstantin | CHF 52,880.–
Klinik für Gynäkologie, Universitätsspital Zürich, Zürich
Screening for novel synthetic lethal treatment approaches in endometrial cancer: a drug library based approach Raineteau Olivier | CHF 70,420.–
Zentrum für Neurowissenschaften Zürich, Universität Zürich und ETH Zürich, Zürich
E proteins as transcriptional targets in experimental gliomas Renner Christoph | CHF 54,696.–
Klinik und Poliklinik für Onkologie, Medizinbereich Innere Medizin-Onkologie, Universitätsspital Zürich, Zürich
Boosting of NY-ESO-1 specific re-directed T-cells Riediger Thomas | CHF 57,880.–
Institut für Veterinärphysiologie, Vetsuisse-Fakultät, Universität Zürich, Zürich
Pharmacological inhibition of inflammatory nuclear factor kB signalling as a possible treatment approach against the cancer anorexia /cachexia syndrome
Sartori Alessandro A. | CHF 78,000.–
Institut für Molekulare Krebsforschung, Universität Zürich, Zürich
MicroRNA-mediated repression of CtIP implications for genomic instability and lymphomagenesis Schäfer Beat | CHF 100,000.–
Abteilung Onkologie, Kinderspital Zürich, Universitäts-Kinderkliniken, Zürich
43
Bubendorf Lukas | Diagnostic significance of ERG expression in biopsies of early detected prostate cancer
Institut für Pathologie, Universitätsspital Basel, Basel Duration: 01. 06. 2012 – 31. 05. 2013
TMPRSS2-ERG gene fusion is found in 50 % of all prostate cancers and plays an important role in the development of these tumours. It has recently become possible to demon- strate the gene fusion simply and directly by means of immunohistochemistry of tissue sections. We studied the frequency and distribution of ERG expression in punch biopsies from 256 patients with prostate carcinomas detected early. We found ERG gene fusion also in approx- imately 50 % of these early carcinomas. In 12 % of the 169 patients with two or three affected biopsies, there were cancer foci with different ERG status (positive and negative), which points to two independently developed cancer foci in the same prostate. Future studies will have to investigate whether this clonal tumour heterogeneity has clinical significance with regard to prognosis or treat- ment planning.
Chiquet-Ehrismann Ruth | SAP-dependent MKL1 signalling in tumour progression
Friedrich Miescher Institut für biomedizinische Forschung (FMI), Basel
Duration: 01. 05. 2012 – 31. 01. 2013
Many cancer patients can be cured as long as their tu- mour has not spread yet to form distant metastases. How- ever, if metastatic foci have developed in distant organs, a cure becomes difficult, since the metastases can no longer be surgically removed. We found that the extra- cellular matrix, the substance that ties our cells together, plays an important role in this process. For example, the extracellular matrix protein tenascin-C is highly enriched in tumours, and the higher the content of tenascin-C the more likely the tumour will become invasive and metasta- size. Of course, tenascin-C is not the only factor involved, and it is our aim to identify more components affecting the metastatic behaviour of tumour cells. Once identified, this will provide the basis for the development of drugs targeting these pro-metastatic factors to interfere with the process. Our aim is to identify novel metastatic pro- teins and signalling pathways and to unravel their mecha- nism of action.